P E Palumbo

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi request reprint Pediatric HIV infection and treatment
    Paul Palumbo
    Department of Pediatrics, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
    Clin Lab Med 22:759-72. 2002
  2. ncbi request reprint Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
    J Infect Dis 179:576-83. 1999
  3. ncbi request reprint Antiretroviral therapy of HIV infection in children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
    Pediatr Clin North Am 47:155-69. 2000
  4. ncbi request reprint Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades
    P Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA
    J Infect Dis 184:1120-6. 2001
  5. ncbi request reprint Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark 07103, USA
    JAMA 279:756-61. 1998
  6. ncbi request reprint Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection
    Paul Palumbo
    Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
    J Infect Dis 196:23-9. 2007
  7. pmc Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure
    Joan H Skurnick
    Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark, NJ 07103 2714, USA
    J Infect Dis 185:428-38. 2002
  8. ncbi request reprint Quantitative RNA testing for diagnosis of HIV-infected infants
    Steven Nesheim
    Emory University School of Medicine, Department of Pediatrics, Infectious Diseases, Epidemiology and Immunology, 69 Butler Street SE, Atlanta, GA 30335, USA
    J Acquir Immune Defic Syndr 32:192-5. 2003
  9. ncbi request reprint Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States
    Deborah Persaud
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 195:1402-10. 2007
  10. ncbi request reprint Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1
    Paul Krogstad
    Department of Pediatrics, University of California Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    AIDS Res Hum Retroviruses 18:413-7. 2002

Detail Information

Publications35

  1. ncbi request reprint Pediatric HIV infection and treatment
    Paul Palumbo
    Department of Pediatrics, UMDNJ New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
    Clin Lab Med 22:759-72. 2002
    ..Significant questions remain and have been largely refocused to the complexities of a chronic disease process. Management invariably requires specialists who must keep abreast of a rapidly evolving information base...
  2. ncbi request reprint Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA
    J Infect Dis 179:576-83. 1999
    ..Nevertheless, plasma RNA and CD4 lymphocyte count together possess strong clinical predictive power and are valuable tools for both the clinician and the evaluation of new therapies...
  3. ncbi request reprint Antiretroviral therapy of HIV infection in children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
    Pediatr Clin North Am 47:155-69. 2000
    ..Efforts are ongoing to develop simpler, more effective therapeutic regimens that suppress and ultimately eradicate infection and that stimulate immune reconstitution...
  4. ncbi request reprint Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades
    P Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA
    J Infect Dis 184:1120-6. 2001
    ..Although no effect of viral resistance on mother-infant transmission was demonstrated, the advent of more-potent drug classes and the potential for the rapid emergence of resistance warrant prospective surveillance...
  5. ncbi request reprint Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
    P E Palumbo
    Department of Pediatrics, University of Medicine and Dentistry of New Jersey, Newark 07103, USA
    JAMA 279:756-61. 1998
    ..Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis...
  6. ncbi request reprint Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection
    Paul Palumbo
    Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
    J Infect Dis 196:23-9. 2007
    ..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches...
  7. pmc Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure
    Joan H Skurnick
    Department of Preventive Medicine and Community Health, New Jersey Medical School, Newark, NJ 07103 2714, USA
    J Infect Dis 185:428-38. 2002
    ..These observations suggest that the primary protective factor is CD8 cell activity in both the HIV-positive donor and the HIV-negative partner. These findings have substantial implications for vaccine development...
  8. ncbi request reprint Quantitative RNA testing for diagnosis of HIV-infected infants
    Steven Nesheim
    Emory University School of Medicine, Department of Pediatrics, Infectious Diseases, Epidemiology and Immunology, 69 Butler Street SE, Atlanta, GA 30335, USA
    J Acquir Immune Defic Syndr 32:192-5. 2003
    ..Quantitative RNA testing can be used for diagnosis in HIV-exposed infants, recognizing the chance for a false-positive test result. It may be most useful as a confirmatory test in infants with another positive diagnostic test result...
  9. ncbi request reprint Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States
    Deborah Persaud
    Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Infect Dis 195:1402-10. 2007
    ....
  10. ncbi request reprint Mother-to-child transmission in the United States of subtypes D and A/G human immunodeficiency virus type 1
    Paul Krogstad
    Department of Pediatrics, University of California Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    AIDS Res Hum Retroviruses 18:413-7. 2002
    ..Non-B subtypes should be considered in the management of HIV-1-infected pregnant women and children to optimize strategies to prevent and treat pediatric HIV-1 infection...
  11. ncbi request reprint CD4/CD8 T-cell ratio predicts HIV infection in infants: the National Heart, Lung, and Blood Institute P2C2 Study
    William T Shearer
    Department of Pediatrics, Section of Allergy and Immunology, Baylor College of Medicine, Houston, TX, USA
    J Allergy Clin Immunol 120:1449-56. 2007
    ..In resource-poor regions of the world, HIV virologic testing is not available...
  12. ncbi request reprint Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
    ..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
  13. pmc Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy
    Ellen Gould Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 28:215-9. 2009
    ....
  14. pmc Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A
    Mainul Hoque
    Department of Biochemistry and Molecular Biology, UMDNJ New Jersey Medical School, NJ 07103, USA
    Retrovirology 6:90. 2009
    ..DOHH activity is inhibited by two clinically used drugs, the topical fungicide ciclopirox and the systemic medicinal iron chelator deferiprone. Deferiprone has been reported to inhibit HIV-1 replication in tissue culture...
  15. pmc Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production
    Neerja Kaushik
    Center for the Study of Emerging and Re Emerging Pathogens, UMDNJ New Jersey Medical School, Newark, New Jersey 07103, USA
    J Virol 76:3881-91. 2002
    ..The mechanism of this inhibition appeared to be regulated at the level of transcription. These results demonstrate the efficacy of PNA(TAR)-transportan as a potential anti-HIV agent...
  16. pmc Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment
    Adriana Weinberg
    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
    J Acquir Immune Defic Syndr 52:17-24. 2009
    ..We sought to identify the immunologic and virologic factors associated with a robust response to hepatitis A virus (HAV) vaccine in children on highly active antiretroviral treatment...
  17. ncbi request reprint Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children
    Joseph A Church
    Department of Pediatrics, Children s Hospital Los Angeles and Keck School of Medicine, University of Southern California, 90027, USA
    Pediatr Infect Dis J 21:653-9. 2002
    ..The fusion inhibitor T-20 is the first in this new class, and the present study is the first to examine chronic s.c. administration of T-20 to HIV-1-infected children...
  18. ncbi request reprint Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004
    Steven R Nesheim
    Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
    Pediatrics 120:100-9. 2007
    ..We sought to determine the impact of highly active antiretroviral therapy on the incidence and prevalence of opportunistic infections in HIV-infected children...
  19. doi request reprint Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004)
    Bill G Kapogiannis
    Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA
    Pediatrics 121:e1229-39. 2008
    ..Highly active antiretroviral therapy has reduced rates of opportunistic infections; less is known about its effect on pediatric bacteremia rates. Thus, we sought to determine its impact on bacteremia incidence in HIV-infected children...
  20. ncbi request reprint Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors
    Janet A Englund
    University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Pediatr Infect Dis J 23:15-22. 2004
    ..We evaluated the development of antiretroviral genotypic resistance and clinical outcome in a subgroup of children involved in a prospective antiretroviral therapy trial (Pediatric AIDS Clinical Trials Group Protocol 152)...
  21. pmc Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection
    Johan K Sandberg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 76:7528-34. 2002
    ..These data indicate that the key immunoregulatory NKT-cell compartment is compromised in HIV-1-infected patients...
  22. ncbi request reprint Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children
    Elaine J Abrams
    Harlem Hospital Center and Columbia University, College of Physicians and Surgeons, New York, New York 10037, USA
    AIDS 17:867-77. 2003
    ..To determine the relationship of maternal health factors and infant antiretroviral treatment to the risk of pediatric disease progression to AIDS or death by 24 months of age...
  23. ncbi request reprint The time to treat the children is now
    Lisa V Adams
    J Infect Dis 195:1396-8. 2007
  24. ncbi request reprint Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol
    Susan Schuval
    Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
    Arch Pediatr Adolesc Med 158:1007-13. 2004
    ..To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection...
  25. ncbi request reprint Maternal versus paternal inheritance of HLA class I alleles among HIV-infected children: consequences for clinical disease progression
    Louise Kuhn
    Gertrude H Sergievsky Center, College of Physicians and Surgeons, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York 10032, USA
    AIDS 18:1281-9. 2004
    ..We investigated whether maternal HLA selection pressures on the virus would adversely influence clinical outcomes of HIV-infected children...
  26. ncbi request reprint Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children
    Joseph A Church
    Childrens Hospital Los Angeles, Division of Clinical Immunology and Allergy, CA 90027, USA
    Pediatr Infect Dis J 23:713-8. 2004
    ..The safety and antiretroviral activity of enfuvirtide treatment of 24 weeks in HIV-1-infected children has been previously documented. Here we present the long term tolerability and safety of enfuvirtide...
  27. ncbi request reprint Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships
    Dolors Soy
    Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, San Francisco, Calif, USA
    Clin Pharmacol Ther 74:569-80. 2003
    ..Our objective was to describe the population pharmacokinetics and pharmacodynamics of enfuvirtide acting on viral ribonucleic acid in children with human immunodeficiency virus 1...
  28. pmc Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics
    E V Capparelli
    San Diego Schools of Medicine and Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92103, USA
    HIV Med 9:214-20. 2008
    ..To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population...
  29. ncbi request reprint GB virus C infection in children with perinatal human immunodeficiency virus infection
    Susan Schuval
    Schneider Children s Hospital, Long Island Jewish Medical Center, New Hyde Park, NY 11042, USA
    Pediatr Infect Dis J 24:417-22. 2005
    ..GB virus C (GBV-C) infection occurs in 20-40% of human immunodeficiency virus (HIV)-infected adults, and coinfection is associated with improved HIV disease outcome...
  30. ncbi request reprint Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age
    Ellen Gould Chadwick
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Pediatr Infect Dis J 24:793-800. 2005
    ..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age...
  31. ncbi request reprint Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis
    Rosalind J Carter
    Medical and Health Research Association, New York, NY 10032, USA
    J Acquir Immune Defic Syndr 41:453-60. 2006
    ..Protease inhibitor (PI)-containing regimens have led to improved survival among HIV-infected children. However, adverse effects, including dyslipidemia, may put children at risk for cardiovascular disease...
  32. ncbi request reprint Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children
    Edmund V Capparelli
    University of California, San Diego, School of Medicine, La Jolla, California, USA
    J Clin Pharmacol 43:133-40. 2003
    ..It was concluded that ZDV oral clearance is reduced in infants compared to older children. This lower clearance leads to higher ZDV exposure in infants and contributes to increased hematologic toxicity...
  33. ncbi request reprint Challenges to re-enrolling perinatally HIV-infected and HIV-exposed but uninfected children into a prospective cohort study: strategies for locating and recruiting hard-to-reach families
    Darcy Freedman
    U S Centers for Disease Control and Prevention, National Center for HIV STD TB Prevention, Atlanta, GA, USA
    Paediatr Perinat Epidemiol 20:338-47. 2006
    ..The PACTS-HOPE cohort will provide opportunities for future research aimed at understanding the unique effects of HIV on the well-being of HIV-infected children...
  34. ncbi request reprint Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
    William T Shearer
    J Allergy Clin Immunol 118:518-21. 2006
  35. pmc Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children
    Courtney V Fletcher
    J Allergy Clin Immunol 119:747-50. 2007